Value of human mitochondrial transcription termination factor 3 and forkhead box protein 3 in predicting the prognosis of non-small cell lung cancer
10.3760/cma.j.issn.1006-9801.2020.01.002
- VernacularTitle: 人线粒体转录终止因子3与叉头框蛋白3在非小细胞肺癌预后预测中的价值
- Author:
Dan SU
1
;
Dongbo LI
1
;
Weiwei ZHANG
2
;
Jingxu CAO
1
Author Information
1. Department of Oncology 1, the Third Medical Center of PLA General Hospital, Beijing 100039, China
2. Department of the Second Section of South Building, the Third Medical Center of PLA General Hospital, Beijing 100039, China
- Publication Type:Journal Article
- Keywords:
Carcinoma, non-small-cell lung;
Mitochondrial proteins;
Forkhead transcription factors;
Human mitochondrial transcription termination factor 3;
Forkhead box protein 3;
Prognosis
- From:
Cancer Research and Clinic
2020;32(1):6-10
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the prognostic value of human mitochondrial transcription termination factor 3 (hMTERF3) and forkhead box protein 3 (Foxp3) in non-small cell lung cancer (NSCLC).
Methods:The clinical data of 88 patients with NSCLC who were admitted to the Third Medical Center of PLA General Hospital from March 2017 to March 2018 were retrospectively analyzed. All patients were diagnosed by pathological puncture. The patients were followed-up by telephone for 12 months, and according to the prognosis, the patients were divided into good prognosis group and poor prognosis group. The pathological tissues were taken from all patients, and the expressions of hMTERF3 and Foxp3 proteins were detected by immunohistochemistry. The expressions of hMTERF3 and Foxp3 in the good prognosis group and the poor prognosis group were compared. Logistic regression model was used to analyze the risk factors of poor prognosis in patients with NSCLC.
Results:Of 88 patients, 61 patients (69.3%) had good prognosis and 27 patients (30.7%) had poor prognosis. The positive expression rate of hMTERF3 in the good prognosis group was 57.4% (35/61), which was significantly lower than that in the poor prognosis group (81.5%, 22/27) (χ 2= 4.766, P= 0.029). The positive expression rate of Foxp3 in the good prognosis group was 55.7% (34/61), which was significantly lower than that in the poor prognosis group (85.2%, 23/27) (χ 2= 7.113, P= 0.008). The proportions of patients with medium and high differentiation or stage Ⅰ- Ⅱ in the good prognosis group were 82.0% (50/61) and 68.8% (42/61), respectively, which were significantly higher than those in the poor prognosis group [48.15% (13/27) and 25.93% (7/27)] (both P < 0.05). Logistic regression analysis showed that the poor differentiation, stage Ⅲ-Ⅳ, hMTERF3-positive and Foxp3-positive were the risk factors for poor prognosis in NSCLC patients (all P < 0.05).
Conclusions:The positive expression rates of hMTERF3 and Foxp3 in patients with good prognosis are lower. The hMTERF3-positive and Foxp3-positive are risk factors for poor prognosis in NSCLC patients.
